Cardio Diagnostics - נכסים נקיים למניה בודדת CDIO

The integration of AI tests into medical protocols ensures a steady stream of orders for Cardio Diagnostics. The GURU.Markets system generates this chart, where the net asset value per ordinary share reflects current capitalization, while the 2.53 indicator determines the parameter status. The strategy is based on the diversification of sales channels as management adjusts expenses amid limited liquidity.

The deployment of the EpiCheck AI platform for predictive DNA marker analysis forms the foundation of high-tech intangible assets for Cardio Diagnostics (CDIO). The trend in the target book value per share, calculated as the difference between total assets and liabilities divided by the number of shares, reflects the real value of net assets, allowing investors to assess the internal capitalization and resilience of Cardio Diagnostics (CDIO) against potential write-downs.